Dublin-listed Open Orphan is currently developing the world’s first challenge study model to test the effectiveness of Covid-19 vaccines that are in development.
These types of studies have the potential to streamline and/or accelerate vaccine development.
Since it added the two companies to its stable, Open Orphan has made cost savings of €2m in Hvivo and €3m in Venn, according to annual results from the group.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).